Przeglądanie według Autor "Korpe, Busra"

Aktualnie wyświetlane 1 - 2 z 2

Determining treatment success in tubal ectopic pregnancies – the predictive value of the delta neutrophil index in single-dose methotrexate therapy
(Publishing Office of the University of Rzeszow, 2024-12) Korpe, Busra; Kose, Caner; Celen, Sevki; Kucukbas, Gokce Naz; Ustun, Yaprak Engin
Introduction and aim. This study assessed the significance of the Delta neutrophil index (DNI) in predicting the effectiveness of single-dose methotrexate (MTX) treatment for tubal ectopic pregnancy. Material and methods. In this retrospective study, 214 women diagnosed with tubal ectopic pregnancies and treated with MTX between 2019 and 2022 were included. Group 1 comprised 88 MTX responders, while group 2 consisted of 86 non-re sponders necessitating surgery. HCG and DNI levels were monitored on day 1, 4, and 7 of MTX treatment and compared be tween the groups. Results. Group 1 exhibited significantly lower HCG and DNI levels compared to group 2 on days 1, 4, and 7 (p<0.001). Both HCG and DNI levels on days 1 and 4 of MTX treatment were significant predictors of treatment failure, with the highest AUC observed for DNI was on day 4. In multivariate logistic regression analysis, elevated DNI levels on day 1 of MTX treatment were associated with a 5.8-fold increased risk, and DNI levels on day 4 were associated with a 4.44-fold increased risk of MTX treatment failure. Conclusion. DNI emerges as a valuable marker for predicting the success of single-dose methotrexate treatment in tubal ecto pic pregnancies, demonstrating superior predictive power compared to HCG.
Factors affecting prognosis in high-intermediate risk endometrial cancer in according to ESMO/ESGO/ESTRO risk classification – FIGO 2023 analysis of survival outcomes and staging dynamics compared to the FIGO 2009 system
(Rzeszów University Press, 2025-06) Guleryuz, Eren Can; Korpe, Busra; Korkmaz, Vakkas
Introduction and aim. Accurate staging is essential for determining treatment strategies and predicting outcomes in endometrial cancer (EC). The FIGO staging system was updated in 2023 to incorporate histological and molecular features. This study evaluates the impact of the FIGO 2023 system on high-intermediate risk endometrioid EC cases and compares its prognostic value with the FIGO 2009 system. Material and methods. A retrospective analysis of 140 high-intermediate risk endometrial cancer cases from two tertiary hospitals was conducted. Patients were reclassified using FIGO 2023, and staging shifts were analyzed. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were assessed using Kaplan-Meier analysis and log-rank tests. Univariate and multivariate regression analyses were performed to identify prognostic factors. Results. Within this high-intermediate risk group, patients were stratified into three groups: group 1 (n=79) consisted of those with LVSI (+) Stage I, group 2 (n=17) included patients with LVSI (-) Stage IB grade 3, and group 3 (n=44) comprised individuals with Stage II. Based on age, a statistically significant difference was identified between group 1 and group 3 (p<0.05), while no statistically significant difference in BMI was observed among the groups (p>0.05). Additionally, there was a statistically significant difference among the groups concerning the type of surgery performed (p<0.05) Although no statistically significant difference in survival outcomes was observed, a trend toward improved risk stratification in OS was noted. Positive lymphovascular space invasion emerged as a key factor influencing upstaging. Conclusion. FIGO 2023 provides a refined staging approach that better aligns with clinical outcomes. Larger prospective studies incorporating molecular profiling are needed to confirm its prognostic utility.